PipelineReview.com3h
Formycon receives EU approval for FYB203 (aflibercept), a biosimilar to Eylea®, under the brand names AHZANTIVE® and Baiama
PLANEGG-MARTINSRIED, Germany I, 2025 I Formycon AG (FSE: FYB, Prime Standard, “Formycon”) and its licensing partner Klinge Biopharma GmbH ...
PipelineReview.com2d
Semaglutide 7.2 mg s.c. achieved 20.7% weight loss in the STEP UP obesity trial, and 18.7% regardless of treatment adherence
BAGSVAERD, Denmark I January 17, 2025 I Novo Nordisk today announced headline results from STEP UP, a phase 3b trial in the global STEP programme. STEP UP is ...
PipelineReview.com2d
FDA approves Lumakras® (sotorasib) in combination with Vectibix® (panitumumab) for chemorefractory KRAS G12C-mutated metastatic colorectal cancer
Pivotal Study Demonstrated the Combination More Than Doubled Progression-Free Survival Compared to Investigated SOC ...
PipelineReview.com3d
Ocugen, Inc. Announces First Patient Dosed in Phase 1 Clinical Trial of OCU200—a Novel Integrin-Targeting Biologic for Diabetic Macular Edema
MALVERN, PA, USA I January 16, 2025 I Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and ...
PipelineReview.com4d
Be Bio Announces Closing of $92M Series C Financing and Completes Transition to a Multi-Program, Clinical Stage Company
CAMBRIDGE, MA, USA I January 15, 2025 I Be Biopharma, Inc. (“Be Bio” or “the Company”), a leader in B Cell Medicines (BCMs), today announced the closing of its $92M Series C financing. The round ...
PipelineReview.com4d
Chromatin Bioscience’s synthetic promoter supports EsoBiotec’s ESO-T01 CAR-T therapy as it enters the clinic
EDINBURGH, UK I January 15, 2025 I Chromatin Bioscience is pleased to announce its ongoing collaboration with EsoBiotec, which has successfully advanced its ESO-T01 in vivo CAR-T candidate into ...
PipelineReview.com4d
Axcynsis Therapeutics Receives FDA Clearance for IND Application of AT03-65, a Differentiated CLDN6-Targeting ADC, Powered by AxcynDOT™ Technology
AT03-65 is the first program utilizing AxcynDOT™, a proprietary payload with a differentiated mechanism of action, to enter clinical development SINGAPORE I January 15, 2025 I Axcynsis Therapeutics ...
PipelineReview.com5d
Bayer’s Pharma Growth Strategy Progressing Well as Pipeline Advances
WHIPPANY, NJ, USA I January 14, 2025 I On the occasion of the 43rd J.P. Morgan Healthcare Conference in San Francisco, Bayer AG announces further progress in its pharmaceutical growth strategy with ...
PipelineReview.com4d
FDA approves Lilly’s Omvoh® (mirikizumab-mrkz) for Crohn’s disease, expanding its use to the second major type of inflammatory bowel disease
In the pivotal Phase 3 VIVID-1 trial, patients treated with Omvoh experienced significant improvement in clinical remission and endoscopic response at one year ...
PipelineReview.com6d
REGENXBIO and Nippon Shinyaku Announce Exclusive Partnership to Develop and Commercialize RGX-121 and RGX-111 for MPS Diseases
ROCKVILLE, MD, USA I January 14, 2025 I REGENXBIO Inc. (Nasdaq: RGNX) and Nippon Shinyaku Co., Ltd. (Nippon Shinyaku) today announced a strategic partnership ...
PipelineReview.com6d
PulseSight Therapeutics announces the initiation of the clinical plan of PST-611, Transferrin Vectorized Therapy for dry AMD/Geographic Atrophy
PARIS, France I January 14, 2025 I PulseSight Therapeutics SAS, an ophthalmology biotech company developing disruptive non-viral vectorized therapies with ...